JAGSNPHARM Intraday Analysis...

JAGSNPHARM Share Price

Open 40.20 Change Price %
High 40.50 1 Day 0.50 1.27
Low 39.35 1 Week -0.55 -1.36
Close 39.75 1 Month 2.30 6.14
Volume 22519 1 Year 5.95 17.60
52 Week High 46.95
52 Week Low 25.80
JAGSNPHARM Important Levels
Resistance 2 40.82
Resistance 1 40.38
Pivot 39.87
Support 1 39.12
Support 2 38.68
NSE INDIA Most Active Stocks
IDEA 119.60 6.22%
JPASSOCIAT 14.75 6.12%
RCOM 36.90 3.22%
JINDALSTEL 116.60 5.76%
SUZLON 18.05 1.69%
BHARTIARTL 366.25 1.45%
ALBK 73.85 4.09%
SOUTHBANK 20.60 0.73%
ICICIBANK 284.50 -0.58%
NHPC 30.15 -0.50%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
FARMAXIND 0.15 50.00%
AUSTRAL 0.35 16.67%
GTLINFRA 4.95 16.47%
NICCO 0.40 14.29%
RKDL 12.95 14.10%
ADLABS 87.90 10.50%
GTL 18.60 9.09%
IBWSL 26.25 8.92%
JAMNAAUTO 217.40 8.70%
More..
NSE INDIA Top Losers Stocks
RAJRAYON 0.25 -16.67%
SRGINFOTEC 0.35 -12.50%
MVL 0.45 -10.00%
MVL 0.45 -10.00%
NOESISIND 0.45 -10.00%
ASIL 0.60 -7.69%
REISIXTEN 0.65 -7.14%
SALONA 62.50 -7.06%
UJAAS 35.10 -5.77%
TARMAT 51.05 -5.64%
More..

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)

JAGSNPHARM Technical Analysis 4
As on 23rd Feb 2017 JAGSNPHARM Share Price closed @ 39.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 37.08 & Strong Buy for SHORT-TERM with Stoploss of 37.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
JAGSNPHARM Target for February
1st Target up-side 39.7
2nd Target up-side 42.64
3rd Target up-side 45.58
1st Target down-side 31.3
2nd Target down-side 28.36
3rd Target down-side 25.42
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Pharmaceuticals - Formulations And Other Stocks in Same Sector
JAGSNPHARM
39.75 0.50 (1.27 %)
LT : Buy
ST : Strong Buy
AMRUTANJAN
578.95 -3.75 (-0.64 %)
LT : Buy
ST : Buy
JAGSNPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
JAGSNPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals - Formulations
Industry
Offical website
JAGSNPHARM Address
JAGSNPHARM
N/A
Interactive Technical Analysis Chart Jagsonpal Pharmaceuticals Limited ( JAGSNPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Jagsonpal Pharmaceuticals Limited
JAGSNPHARM Business Profile
Jagson Pharma is in the Pharmaceuticals - Formulations sector. Jagsonpal Pharmaceuticals (JAGSONPH) is a pharmaceutical company producing drugs and formulations. The company was incorporated in 1978 as a private limited company and went public in 1986. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It focuses on several therapeutic groups like anti-arthritics, anti-inflammatories, analgesics, anti-spasmodics, progesterones, anabolic steroids, anesthetics and anti-fungals. Top selling brands include Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR. The company manufactures active pharmaceutical ingredients (APIs) like Allylestrenol, Disulfiram, Tolnaftate, ..etc. The bulk drug range includes dextropropoxyphene HCl, tolnaftate, dextropropoxyphene napsylate and thiopental sodium. The manufacturing facility in Delhi is WHO and GMP-certified for the production of various dosage forms and bulk drugs and intermediates. The company also maintains a number of dedicated contract manufacturing facilities around the globe. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe. The distribution network in India is comprised of over 1,500 authorized stockists who are serviced by depots. The products are retailed at over 125,000 pharmacies. The company is represented by 2,500 agents worldwide and has offices in three continents. The company`s operations span Russia, USA, Brazil, Ukraine, Sri Lanka, Cameroon, Argentina, Thailand, Germany, Switzerland, Korea, Egypt and Vietnam. The company has a sales office in New York through which it services North and Latin American clients and in Belarus, it has an operation center with a sales and distribution team. The current market capitalisation stands at Rs 23.71 crore.The company has reported a standalone sales of Rs 36.79 crore and a Net Profit of Rs 0.01 crore for the quarter ended Sep 2013. The company management includes R P S Kochhar - Chairman & Managing Director, S K Goyal - Director, Govind Deo - Additional Director, Bharat Sinh - Additional Director, Ishpal Singh Ghai - Additional Director. It is listed on the BSE with a BSE Code of 507789 and the NSE with an NSE Code of JAGSNPHARM. Its Registered office is at T-210 J, Shahpur Jat , New Delhi,Delhi - 110049.